Close mobile menu×
Close mobile menu

Yvonne Saenger, MD

Board Certifications: 
Medical Oncology, Internal Medicine
Expertise in: 
Pancreatic Cancer, Melanoma, Liver Cancer, Cancer Care
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-5098
New Patients: 
(212) 305-5098
Existing Patients: 
(646) 317-6313

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Medical Oncology
  • Internal Medicine

Clinical Expertise

  • Pancreatic Cancer
  • Melanoma
  • Liver Cancer
  • Cancer Care
  • Neuroendocrine Carcinoma

Specialties

Education & Training

  • MD, Columbia University College of Physicians and Surgeons
  • Internship: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: Memorial Sloan-Kettering Cancer Center
  • Fellowship: Johns Hopkins Medical Institutions

About Yvonne Saenger

As Director of Melanoma Immunotherapy and a member of the Pancreas Center, Dr. Saenger is a pioneer in the field of cancer immunotherapy. Dr. Saenger's laboratory is focused on developing new tools for the clinic designed to bring the benefits of immunotherapy to larger patient populations, in particular patients with pancreas cancer and patients with melanoma who do not respond to currently available immunotherapies.

Dr. Saenger has recently developed a 53 -immune gene panel predictive of clinical outcomes in melanoma, and this immune gene panel is the basis for a multi-center validation trial in collaboration with the National Cancer Institute. Dr. Saenger's melanoma research is in the area of immunogenomics and she is working in collaboration with network biologists to better understand the networks of immune genes determinative of patient outcome. She has proposed CD2 as a novel biomarker in melanoma and is currently funded to use NanoString technology, a methodology whereby genomic information can be extracted from formalin fixed banked patient samples, to validate her 53-gene panel in a large population of patients from the Eastern Cooperative Oncology Group E1697 study. Her current work focuses on understanding how immunotherapy causes perturbations in immune gene expression in blood and tumor samples.

Dr. Saenger also has a strong research interest in oncolytic viruses and the benefits of combining oncolytic viruses with checkpoint blockade using anti-PD1 and anti-CTLA-4. She is studying these therapies in mouse models of melanoma and has recently initiated an initiative to administer oncolytic virus to pancreas cancer patients. Combining in situ vaccination with a live virus with checkpoint blockade offers the opportunity to combat immunosuppression within the tumor bed, a serious barrier to efficacy of immunotherapy in pancreatic cancer.

Clinically, Dr. Saenger specializes in cancer immunotherapy and she tailors her treatments to individual patient needs based on available immune based medicines. Dr. Saenger's research is supported by a Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute, a Cancer Immunology Innovator award American Association for Cancer Research, and the Melanoma Research Alliance. She has also been supported in the past by the Dermatology Foundation. Dr. Saenger speaks nationally and internationally on topics in immunotherapy and biomarkers.

Academic Titles

  • Assistant Professor of Medicine at CUMC

Administrative Positions

  • Director, Melanoma Immunotherapy

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • NYP Employee Plan
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs Plan

Amida Care

  • Special Needs Plan

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs Plan

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
New York, New York 10032
Phone:
(212) 305-5098
Fax:
(212) 305-6891
Primary

Research

Grants

QUANTITATIVE MULTIPLEX IMMUNOHISTOCHEMISTRY (MIHC) EVALUATION OF THE TUMOR MICROENVIRONMENT (TME) IN PRETREATMENT SAMPLES OF PATIENTS WITH METASTATIC BREAST CANCER (MBC) AND SEROUS OVARIAN CARCINOMA TREATED ON ERIBULIN-LF PHASE 1 STUDY (NCT01945710). (P&S Industry Clinical Trial)

Feb 12 2018 - Feb 12 2023

PROBING IMMUNE SIGNATURES IN HIGH RISK PRIMARY MELANOMA TUMORS TO ESTABLISH PROGNOSTIC BIOMARKERS AND MECHANISMS OF SUCCESSFUL IMMUNE SURVEILLANCE (P&S Industry Clinical Trial)

Jul 27 2017 - Jul 27 2022

A PHASE I STUDY OF TALIMOGENE LAHERPAREPVEC ADMINISTERED ENDOSCOPICALLY IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC PANCREAS CANCER REFRACTORY TO AT LEAST ONE CHEMOTHERAPY REGIMEN (P&S Industry Clinical Trial)

May 1 2017 - May 1 2022

ELUCIDATING GENETICS OF RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN LUNG CANCER (Federal Gov)

Jan 18 2017 - Dec 31 2021

PH1 STUDY OF T-VEC GIVEN ENDOSCOPICALLY FOR ADVANCED PANCREATIC CANCER IN 17248 (11/21/2016) (Federal Gov)

Aug 1 2018 - Jul 31 2021

A PROGNOSTIC MRNA IMMUNE SIGNATURE FOR RESECTED STAGE II-III MELANOMA (Federal Gov)

Jun 13 2019 - May 31 2021

CANCER CENTER SUPPORT GRANT (Federal Gov)

Jul 1 2014 - Jun 30 2019

AN INVESTIGATOR-INITIATED STUDY TO EVALUATE GENETIC EXPRESSION OF GENOMIC MARKERS OF IMMUNE INFILTRATION BEFORE AND AFTER TREATMENT OF ACTINIC KERATOSIS WITH IMIQUIMOD 3.75% CREAM (Private)

Jun 18 2018 - Dec 18 2018

DEFINING BIOMARKERS OF IMMUNE ACTIVATION DURING ANTI-PD1+TVEC THERAPY (Private)

Sep 16 2015 - Sep 15 2018

PHASE II TRIAL OF ADXS11-001 VACCINE FOR HPV-RELATED OROPHARYNGEAL CANCER (Federal Gov)

Sep 1 2015 - Jul 31 2018

DEFINING BIOMARKERS OF IMMUNE ACTIVATION DURING ANTI-PD1+TVEC THERAPY (Private)

May 1 2015 - Apr 30 2018

EFFICACY OF INT230-6 COMBINED WITH IMMUNOTHERAPY IN A B16 MELANOMA MOUSE MODEL (Private)

Jun 27 2016 - Jun 26 2017

SOLUBLE SCAVENGER-LIKE LYMPHOCYTE RECEPTORS AS NOVEL IMMUNOMODULATORY AGENTS IN CANCER (Private)

May 8 2014 - May 7 2017

ESTABLISHING IMMUNE BIOMARKERS FOR MELANOMA RECURRENCE AND SURVIVAL (Private)

Aug 1 2014 - Jul 31 2016

ESTABLISHING EFFICACY AND MECHANISMS OF TALIMOGENE LAHERPAREPVEC COMBINED WITH ANTI PROGRAMMED DEATH -1 AND BRAF INHIBITION IN SPONTANEOUS MURINE MELANOMA (Private)

Jul 14 2015 - Jul 5 2016